Optibiotix Health Share Discussion Threads

[rafboy] 03/11/2017 16:08

You could well be right as we have just gone to 74p to sell!

[parob] 03/11/2017 16:02

I'm sure some games are being played here and think the 100K earlier was also a buy. I tried a dummy sell of 25K shares just after the 2 X 50K and was quoted 72.1p so there's no way you'd get 72.5p for 100K. Just my take.

[rafboy] 03/11/2017 16:02

Back up we go, right see saw.

[rafboy] 03/11/2017 15:15

Now a 100K sell? As you say large trades for a Friday afternoon. Yes, I agree we must be close to a decent push north.

[parob] 03/11/2017 15:08

Sneaked in on a quiet Friday afternoon raf! Convinced we'll be hitting 3 month highs next week.

[rafboy] 03/11/2017 15:03

Two 50K buys, not a rollover as at same price!

[judijudi] 03/11/2017 14:36

Great minds think alike
:)

[parsnip1] 03/11/2017 14:33

Best way to grab their attention is to come to their country. Partial listing in NY would do wonders....

[loungeact] 03/11/2017 12:37

Americans can buy guns using a library card. It can take time for things to sink in them for them :)

[judijudi] 03/11/2017 12:27

When people do realise what is going on there will be a scramble for shares
I have no idea what will trigger the big push upwards but with only 80mill shares in issue (a tiny amount these days) and a lot of these shares are tightly held, the rise could be impressive and just as importantly, sustained

[owenmo] 03/11/2017 12:22

Americans in a daze these days; unsurprisingly. Wouldn't you have thought the presentation in San Diego wold have triggered even a trickle of buys on the part of street-wise US cousins! We've had a veritable belly full of micribiome coverage/publicity - to no effect Opti share price wise. What is going on?

[someuwin] 03/11/2017 10:42

Gut bacteria 'boost' cancer therapy

Bacteria living in the murky depths of the digestive system seem to influence whether tumours shrink during cancer therapy, say French and US researchers.

They tested the microbiome - the collection of microscopic species that live in us - in cancer patients...

[2350220] 03/11/2017 09:57

Ta Elrico,
I was going to add in that post, that we have our own reliable reporters here on this thread, with the likes of yourself, Parob and so many others.

John

[elrico] 03/11/2017 09:37

Mouse - that Telegraph piece is very disturbing....I have sent a plea to SOH, on behalf of my grandchildren.

[elrico] 03/11/2017 09:36

John - Capital Network is from the same stable as Proactiveinvestors. They appear to be using most of their own sources, along with TW and snippets from my articles, but mainly their own from SOH interviews.

[jestercat2] 03/11/2017 09:25

Thanks for the link to the report. For me it's interesting that it actually gives some revenue projections which is something we've been lacking in the past.

[2350220] 03/11/2017 08:44

Thanks for the interesting links today.
Just looked through the Capital report, and had a look at the info at the bottom of the page:
"Important – This report has been commissioned by Optibiotix Health Plc and prepared and issued by Capital Network for publication globally.
All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however, we do not guarantee the accuracy or completeness of this report."

The reason I mention it, is that it's not impartial, as I mistakenly thought.
John

[mouse20] 03/11/2017 08:28

Posted today

[mouse20] 03/11/2017 07:20

Daily Telegraph today...I'm sure there must be an alternative treatment...

STATINS should be given to thousands of children by the age of 10 under radical new NHS guidance.
GPs are being urged to identify boys and girls with an inherited risk of high cholesterol, amid warnings that most cases go undetected.
Estimates suggest up to 260,000 people, including 50,000 children, suffer genetic defects that affect the body’s ability to break down cholesterol. Guidance issued by the National Institute for Health and Care Excellence (Nice) today says statins should be offered to reduce the risk of heart conditions or stroke in midlife.

[joyjoy13] 03/11/2017 01:52

loungeact
Thanks for posting 👍
Above article

[joyjoy13] 03/11/2017 01:50

Found this article of interest...

Gut bacteria 'boost' cancer therapy - BBC News

[1bokke] 02/11/2017 23:50

Haven't checked today's comments so if this has been posted earlier then apologies..Very interesting article. http://dailym.ai/2AaSx8z

[loungeact] 02/11/2017 23:43

OptiBiotix Release: New Research On Synthetic Prebiotics Presented At US Microbiome R&D Event. - Published: Nov 02, 2017 -

Professor Bob Rastall, Professor of Food Biotechnology at the University of Reading, has presented research on an exciting, emerging area of microbiome modulation at the 5th Microbiome R&D and Business Collaboration Forum in San Diego. Professor Rastall’s presentation explored the possibility of developing optimised synbiotics, known as optibiotics, which have the potential to be far more effective than existing probiotics at achieving targeted health benefits, including reducing cholesterol and blood pressure.

Synbiotics are combinations of a probiotic and a prebiotic, which both are targeted at the same healthcare benefit. Most synbiotics to date have been mixtures of readily available carbohydrates and commercial probiotics, often driven by ease of availability rather than proven efficacy. Professor Rastall’s presentation asserts that a more effective approach to the development of synbiotics would be to use the metabolic machinery of the target bacterial strain to generate an oligosaccharide (prebiotic) mixture that is metabolizable by that producing bacterial strain. Such optimized mixtures would be considered optibiotics.

Professor Rastall’s proposals about the development of optimised synbiotics have already been put into practice. Research from the University of Reading, Department of Food and Nutritional Sciences, and OptiBiotix Health, has previously shown that a naturally synthesised prebiotic can selectively increase the growth of the cholesterol-reducing probiotic, Lactobacillus plantarum LPLDL®, as well as its enhancing its cholesterol-reduction activity. The researchers used reverse enzyme technology to synthesise a prebiotic, LPGOS, to selectively enhance the growth and cholesterol-reducing activity of the LPLDL® probiotic.

LPLDL® was selected from over 4,000 other bacterial strains because of its ability to lower both cholesterol and blood pressure. In a previous study, it was found to reduce LDL cholesterol by up to 13.9%, and blood pressure by 5.1%. When combined with the LPGOS prebiotic, LPLDL® was found to increase the cholesterol lowering effect by over threefold in a 24-hour period.

Professor Rastall, who was involved in this synbiotic research, commented, “Using β‐galactosidases expressed by LPLDL® (LPGOS) we achieved the synthesis of GOS modulator that works in true synergy with the parent strain, not only increasing its population but also impacting on the biological activity the probiotic was selected for. This is the first time that true synergy has been demonstrated for a synbiotic, and suggests that these far more effective optimised synbiotics, will achieve greater health benefits than current probiotic and prebiotic products.”

[parob] 02/11/2017 19:16

From the link I posted earlier:A rich deal pipeline is likely to translate in material revenue growth (£1mln+) within 12 months.We are confident that the current rich deal pipeline will trigger a significant revenue uptake in the coming quarters. Based on our understanding, a typical commercial deal could generate annual revenue in the £250,000 - £500,000 range; we also note that larger deals in the multi-million range are within the Company's current reach.We expect the income generated by the ongoing commercial expansion to provide the resources needed to accelerate OptiBiotix commercial push, including the potential acquisition on new IP and products.From a financial perspective, OptiBiotix, with approx. £1.9mln of cash at the end of May 2017 and an estimated cash burn of c. £90k/month, is self-funded well into 2018, excluding any potential income from new deals.